Answers are grounded in this paper and cite their sources.
Literature review reveals therapeutic activities of ginkgolide A across inflammatory, neurological, and cardiovascular conditions, indicating its promise as a clinical lead compound.
Ginkgolide A is a highly active platelet activating factor antagonist cage molecule which was isolated from the leaves of the Ginkgo biloba L. It is known for its inflammatory and immunological potentials. This review aims to sketch a current scenario on its therapeutic activities on the basis of scientific reports in the databases. A total 30 articles included in this review suggests that ginkgolide A has many important biological activities, including anti-inflammatory, anticancer, anxiolytic-like, anti-atherosclerosis and anti-atherombosis, neuro- and hepatoprotective effects. There is a lack of its toxicological (e.g. toxicity, cytotoxicity, genotoxicity and mutagenitcity) profile. In conclusion, ginkgolide A may be one of the potential therapeutic lead compounds, especially for the treatment of cardiovascular, hepatological, and neurological diseases and disorders. More studies are necessary on this hopeful therapeutic agent.
No takes yet. Share an insight, caveat, or question.
Sarkar et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: